Travere Positioned To Seek Accelerated Approval In Rare Kidney Disorder

 
• By Joseph Haas

With interim Phase III data showing threefold reduction in proteinuria reduction compared to SOC, Travere plans to seek accelerated US and EU approval of sparsentan in immunoglobulin A nephropathy.

Human kidney on scientific background. 3d illustration
Travere's sparsentan is one of several candidates to be the first approved IgAN therapy

More from Clinical Trials

More from R&D